New Genmab/Seagen drug will cost up to USD 120,000

Patients being treated for cervical cancer in the US will pay a considerable sum to be treated with Genmab and Seagen's newly approved drug Tivdak, which the two companies will market together in the country.

Photo: Lars Møller / Genmab / PR

This week's FDA approval of cervical cancer drug Tivdak is a historic one for Genmab. Although the company does have other approved drugs on the market – Darzalex, Kesimpta and Tepezza – this marks the first time that the company will market one of its own drugs.

In the US, Genmab and its partner Seagen will share marketing and sales responsibilities for the drug. This means Genmab will need to activate the sales capacity it has been building up over the past few years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs